Last reviewed · How we verify
RhEGF
RhEGF is a recombinant human epidermal growth factor that promotes tissue regeneration and wound healing in oral and dental tissues.
RhEGF is a recombinant human epidermal growth factor that promotes tissue regeneration and wound healing in oral and dental tissues. Used for Periodontal bone defects and regeneration, Oral and dental tissue healing following surgical procedures.
At a glance
| Generic name | RhEGF |
|---|---|
| Also known as | EGF+Collagen, EASYEF® |
| Sponsor | SVS Institute of Dental Sciences |
| Drug class | Growth factor |
| Target | EGFR (Epidermal Growth Factor Receptor) |
| Modality | Small molecule |
| Therapeutic area | Dentistry / Periodontal / Oral Surgery |
| Phase | Phase 3 |
Mechanism of action
RhEGF binds to epidermal growth factor receptors on epithelial and fibroblast cells, stimulating proliferation, migration, and differentiation to accelerate tissue repair. This mechanism is particularly applied in dental and periodontal regeneration, where it enhances bone and soft tissue healing following surgical or pathological defects.
Approved indications
- Periodontal bone defects and regeneration
- Oral and dental tissue healing following surgical procedures
Common side effects
- Local tissue irritation
- Infection at application site
Key clinical trials
- A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence (EARLY_PHASE1)
- EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer (EARLY_PHASE1)
- CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer (PHASE1, PHASE2)
- Comparing the Efficacy and Safety of Fractional Picosecond Laser and Gold Microneedle in the Treatment of Acne Scars (NA)
- Efficacy and Safety Evaluation of the Intralesional Recombinant Human Epidermal Growth Factor (rhEGF) in Subjects With Diabetic Foot Ulcer. (PHASE3)
- Efficacy and Safety Evaluation of EASYEF® in Acute Wound (Split-thickness Skin Graft Donor Site) (NA)
- A Randomized Controlled Clinical Trial of Surgery Versus Conservative Treatment for Mild and Moderate-grade Nasopharyngeal Necrosis (NA)
- Pharmacokinetics, Safety, and Tolerability of rhEGF Eye Drops in Healthy Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |